We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
- Authors
Chen, Xuewei; Liu, Liping; Guo, Zhihua; Liang, Wenhua; He, Jiaxi; Huang, Liyan; Deng, Qiuhua; Tang, Hailing; Pan, Hui; Guo, Minzhang; Liu, Yang; He, Qihua; He, Jianxing
- Abstract
Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-induced neutropenia, diarrhea and IRI-based chemotherapy tumor response (TR) in Asians with lung cancer remains controversial. In this meta-analysis, we found a higher risk of neutropenia and diarrhea with IRI-based chemotherapy in Asians with lung cancer carrying the UGT1A1*6 polymorphism. However, UGT1A1*28 showed a weak correlation with diarrhea, but no significant correlation with neutropenia. Neither UGT1A1*6 nor UGT1A1*28 is associated with IRI-based chemotherapy TR. These data suggest that the UGT1A1*28 polymorphism may not be a suitable biomarker to predict IRI-induced toxicities and chemotherapy TR in Asians, while UGT1A*6 polymorphism is associated with a higher risk of IRI-induced neutropenia and diarrhea, but not IRI-based chemotherapy TR.
- Subjects
IRINOTECAN; GENETIC polymorphisms; ASIANS; LUNG cancer; META-analysis; PHARMACOGENOMICS; THERAPEUTICS; DISEASES
- Publication
Cancer Chemotherapy & Pharmacology, 2017, Vol 79, Issue 6, p1109
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-017-3306-9